Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Neoplasm, Residual 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1

Interventions

Carboplatin 784Pemetrexed 607Cisplatin 545Paclitaxel 491pembrolizumab 464Docetaxel 440Gemcitabine 328Erlotinib Hydrochloride 307Radiotherapy 258Nivolumab 244Bevacizumab 233osimertinib 178Drug Therapy 164durvalumab 157atezolizumab 135Gefitinib 134Radiosurgery 133Vinorelbine 111Cetuximab 97130-nm albumin-bound paclitaxel 94Ipilimumab 86Magnetic Resonance Spectroscopy 84Taxes 79Surgical Procedures, Operative 74Afatinib 68Albumin-Bound Paclitaxel 66Specimen Handling 61Etoposide 61Cyclophosphamide 60tislelizumab 59

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × NKTR-255 × Clear all
NCT05676749 2026-01-05

C-TIL051 in Non-Small Cell Lung Cancer

AbelZeta Inc.

Phase 1 Terminated
1 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡